Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Not Recruiting

Trial ID: NCT01525082


The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.

Official Title

A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Stanford Investigator(s)

Shagufta Shaheen
Shagufta Shaheen

Clinical Assistant Professor, Medicine - Oncology

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine



   - Histologically-confirmed pancreatic neuroendocrine tumors that are moderately- or

   - Metastatic or unresectable disease

   - If prior surgical resection > 5 years before the development of metastatic disease, a
   separate (recent) histological or cytological confirmation of metastatic disease is

   - If there is substantial clinical ambiguity regarding the nature or source of apparent
   metastases, clinicians should consider biopsy of lesions to establish diagnosis of
   metastatic disease

   - The site of previous radiotherapy, if the only site of disease, has evidence of
   progressive disease

   - If prior sunitinib and everolimus has been administered, a 2-week wash-out period is
   required prior to 1st dose on this study

   - If prior liver-directed therapies (ie, chemoembolization, radioembolization), target
   lesions in the liver have demonstrated growth since the liver-directed treatment

   - If prior peptide receptor radionuclide therapy (PRRT), target lesions in the liver
   have demonstrated growth since the liver-directed treatment

   - Low-dose aspirin (≤ 325 mg/d) may be continued in subjects at higher risk for arterial
   thromboembolic disease.

   - Primary or metastatic tumor lesion measurable in at least 1 dimension, within 4 weeks
   prior to entry of study.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

   - ≥ 18 years of age.

   - Laboratory values as follows, ≤ 2 weeks prior to randomization:

   - Absolute neutrophil count (ANC) ≥ 1.5 x 10e9/L (≥ 1500/mm³)

   - Platelets (PLT) ≥ 100 x 10e9/L (≥ 100,000/mm³)

   - Hemoglobin (Hgb) ≥ 9 g/dL

   - Serum creatinine ≤ 1.5 x upper limit of normal (ULN)

   - Serum bilirubin ≤ 1.5 x ULN

   - Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) ≤ 3.0 x ULN
   (≤ 5.0 x ULN if liver metastases present). Note: endoscopic retrograde
   cholangiopancreatography (ERCP) or percutaneous stenting may be used to normalize the
   liver function tests

   - Urine dipstick or urinalysis for protein, value must be 0, trace, or 1+ protein to
   enroll. EXCEPTION: if ≥ 2+ must check 24-hour urine protein and must be < 1 g

   - Life expectancy ≥ 12 weeks

   - Ability to give written informed consent according to local guidelines

   - If any prior therapy-related toxicities, must have recovered from all

EXCLUSION CRITERIA Disease-Specific Exclusions

   - Prior bevacizumab; fluoropyrimidines (eg, capecitabine or 5-fluorouracil, 5FU); or

   - Poorly-differentiated or high-grade pancreatic neuroendocrine tumors

   - Prior full field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior
   to enrollment

   - Diagnosis of another malignancy, unless > 3 years earlier and has been disease-free
   for > 6 months following the completion of curative intent therapy, specific
   eligibility exceptions as follows:

   - Curatively-resected non-melanomatous skin cancer

   - Curatively-treated cervical carcinoma in situ

   - Organ-confined prostate cancer with no evidence of recurrent or progressive disease
   based on prostate-specific antigen (PSA) values, if hormonal therapy has been
   initiated or a radical prostatectomy has been performed

   - Other primary solid tumor curatively treated with no known active disease present and
   no treatment administered for > 3 years

   - Concurrent use of other investigational agents and patients who have received
   investigational drugs ≤ 4 weeks prior to enrollment

   - Known hypersensitivity to capecitabine, temozolomide, or any component of the

   - Known deficiency of dihydropyrimidine dehydrogenase Bevacizumab-specific Exclusions

   - Inadequately-controlled hypertension (defined as systolic blood pressure >150 mmHg
   and/or diastolic blood pressure > 100 mmHg)

   - Prior history of hypertensive crisis or hypertensive encephalopathy

   - New York Heart Association (NYHA) Grade II or greater congestive heart failure

   - History of myocardial infarction or unstable angina within 6 months prior to Day 1

   - History of stroke or transient ischemic attack within 6 months prior to Day 1

   - Known central nervous system (CNS) metastases

   - Significant vascular disease (eg, aortic aneurysm, requiring surgical repair or recent
   peripheral arterial thrombosis) within 6 months prior to Day 1

   - History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month
   prior to Day 1

   - Evidence of bleeding diathesis or significant coagulopathy (in the absence of
   therapeutic anticoagulation)

   - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
   prior to Day 1 or anticipation of need for major surgical procedure during the course
   of the study

   - Core biopsy or other minor surgical procedure, excluding placement of a vascular
   access device, within 7 days prior to Day 1

   - History of abdominal fistula or gastrointestinal perforation within 6 months prior to
   Day 1

   - Serious, non-healing wound, active ulcer, or untreated bone fracture

   - Known hypersensitivity to any component of bevacizumab General Medical Exclusions

   - Inability to comply with study and/or follow-up procedures

   - Current, recent (within 4 weeks of the first infusion of this study), or planned
   participation in an experimental drug study

   - Pregnant or lactating/breast feeding

   - Lack of effective contraception men or women of child-bearing potential

   - Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as
   exhibiting ongoing signs/symptoms related to the infection and without improvement,
   despite appropriate antibiotics or other treatment)

   - Known history of HIV, HBV, or HCV

   - Current, ongoing treatment with full-dose warfarin. However, patients may be on stable
   doses of a low-molecular weight heparin are allowed [eg, (enoxaparin (Lovenox)].


biological: bevacizumab

drug: Capecitabine

drug: Temozolomide

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.